Tags : Mundipharma

PharmaShots Weekly Snapshot (January 13-17, 2020)

1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart 2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, […]Read More

Mundipharma Collaborates with Samsung Bioepis to Commercialize Multiple Biosimilar Candidates

Shots: Mundipharma to get exclusive commercialization rights for Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong while Samsung Bioepis will remain MAH, responsible for the development, regulatory and manufacturing activities of therapies The biosimilar candidates include SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab) targeting immunology & oncology The collaboration combines Samsung […]Read More

PharmaShots Weekly Snapshot (January 06-10, 2020)

Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb Published: Jan 10, 2020 | Tags: Nektar Therapeutics, Signs, Clinical Trial, Collaboration, Bristol-Myers Squibb 2. Eli Lilly to Acquire Dermira for $1.1B Published: Jan 10, 2020 | Tags: Eli Lilly, Acquire, Dermira, $1.1B 3. Bayer Signs a Three Year Multi Target AI-based Agreement with Exscientia to Treat […]Read More

Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution

Shots: Mundipharma to get exclusive rights to market and distribute Biosolution’s CartiLife in South Korea. In May 2016, the companies signed commercialization agreement for allogeneic keratinocyte cell therapy product, KeraHeal-Allo and is the second agreement signed presently The focus of the agreement is to include Biosolution’s CartiLife in the Mundipharma’s portfolio of orthopedic care CartiLife […]Read More

Top Biosimilar Companies with Approved and Pipeline Products in the

Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. The companies are focusing on […]Read More

Insights+ Key Biosimilars Events of October 2019

Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the […]Read More

Mundipharma’s Pegfilgrastim Mundipharma (biosimilar, pegfilgrastim) Receives CHMP Positive Opinion for

Shots: The Mundipharma biosimilar Pegfilgrastim Mundipharma (6mg solution injection) will be authorized for sales in the EU to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy In Nov’2018, Mundipharma has received EC’s approval with trade name Pelmeg having same indication & same dose, which also […]Read More

Insights+ Key Biosimilars Events of July 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” which are biologically like biologics. They possess similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots have […]Read More

Mundipharma and Prestige Enters into an Exclusive License and Supply

Shots: Mundipharma to get exclusive rights to distribute, market and commercialize Tuznue in selected EU countries following marketing authorization, including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland and Austria The EMA approval of Tuznue is based on positive results confirming it as a biosimilar to Herceptin in terms of clinical response and PK with […]Read More

Egis Pharmaceuticals Signs an Exclusive Distribution Agreement with Mundipharma for

Shots: Egis Pharmaceuticals acquires exclusive distribution rights of Pelmeg (pegfilgrastim, biosimilar) from Mundipharma to launch the product in four CEE markets i.e. Hungary, Romania, including Latvia and Lithuania  Pelmeg is the fourth biosimilar commercialized by Mundipharma, originally developed by Cinfa Biotech. In 2018, Mundipharma acquired Cinfa Biotech for the expansion of its footprints in biosimilars […]Read More